6864 Stock Overview
Anti-Microbial Savior BioteQ Co., Ltd. se dedica a la investigación y desarrollo de productos farmacéuticos en Taiwán.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Anti-Microbial Savior BioteQ Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$27.10 |
| 52 Week High | NT$43.10 |
| 52 Week Low | NT$22.50 |
| Beta | 0 |
| 1 Month Change | -3.90% |
| 3 Month Change | 7.75% |
| 1 Year Change | -32.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6864 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0.9% | 0.8% | 0.4% |
| 1Y | -32.4% | -21.0% | 27.1% |
Rentabilidad frente al sector: 6864 obtuvo unos resultados inferiores a los del sector TW Biotechs , que el año pasado arrojó un rendimiento del -17.5%.
Rentabilidad vs. Mercado: 6864 obtuvo unos resultados inferiores a los del mercado TW, que fue del 20.3% el año pasado.
Price Volatility
| 6864 volatility | |
|---|---|
| 6864 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 4.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in TW Market | 8.2% |
| 10% least volatile stocks in TW Market | 1.9% |
Precio estable de las acciones: 6864 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: 6864(6%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de TW.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | n/a | https://www.ams-bioteq.com |
Anti-Microbial Savior BioteQ Co, Ltd. se centra en la investigación y el desarrollo de productos farmacéuticos en Taiwán. La empresa se fundó en 2018 y tiene su sede en Kaohsiung, Taiwán.
Anti-Microbial Savior BioteQ Co., Ltd Fundamentals Summary
| 6864 fundamental statistics | |
|---|---|
| Market cap | NT$677.50m |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6864 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6864 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6864 perform over the long term?
See historical performance and comparison